News

Sigyn Therapeutics Announces Completion of Merger with Reign Resources

Sigyn is Focused on the Treatment
of Sepsis and Other Life-Threatening Inflammatory Conditions That are Not Addressed
with Approved Drug Therapies

Trading to Commence Tomorrow
Under the Ticker Symbol “SIGY”

San Diego, California – (NewMediaWire) – October 19, 2020 – Sigyn
Therapeutics, Inc., a medical technology company focused on the treatment of life-threatening
inflammatory conditions, today announced the completion of its previously disclosed
merger with Reign Resources Corporation (OTCMarkets: RGNP). The new combined company
will operate under the name Sigyn Therapeutics, Inc. (Sigyn) and will commence trading
tomorrow, October 20th under the ticker symbol SIGY.

Sigyn was established to address
a significant unmet need in global health; the treatment of life-threatening inflammatory
conditions precipitated by Cytokine Storm Syndrome (“the Cytokine Storm”), a hyperactive
immune response that can induce multiple organ failure and cause death.  The annual market opportunity for a therapeutic
strategy to prevent or mitigate the Cytokine Storm exceeds $20 billion. 

Sigyn Therapy™ is a development-stage
blood purification therapy created to overcome the limitations of previous drugs
and devices to treat life-threatening inflammatory conditions, including sepsis,
the #1 cause of in-hospital deaths.  Mechanistically,
Sigyn Therapy is designed to deplete the presence of a broad-spectrum of inflammatory
factors from the human circulatory system. This includes pro-inflammatory cytokines,
cytokine aggregates, endotoxin and larger CytoVesicles that transport cytokines
and other inflammatory cargos in the bloodstream.

Beyond sepsis, Cytokine Storm related
therapeutic opportunities may include, but are not limited to virus-induced Cytokine
Storm (a leading cause of COVID-19 deaths), bacteria-induced Cytokine Storm, acute
respiratory distress syndrome (ARDS) and acute forms of liver failure, including
hepatic encephalopathy.  Sigyn Therapy may
also be a candidate to stabilize or extend the life of patients waiting for the
identification of a matched liver for transplantation.  In such a scenario, Sigyn Therapy™ would serve
as a bridge-to-liver transplant. Cytokine Storm Syndrome may also be induced by
trauma, severe burns, acute pancreatitis, adverse drug reactions, cancer immunotherapies,
cancer cachexia, acute kidney injury (AKI) and severe pneumonia.

“The completion of this merger fulfills
our objective to establish Sigyn Therapeutics as a publicly-traded company,” stated
Sigyn Chairman and CEO, Jim Joyce. “To further the advancement of Sigyn Therapy,
we are initiating a series of studies to reinforce the capability of our technology
and to support our regulatory milestone objective to submit an Investigation Device
Exemption (IDE) to The United States Food and Drug Administration (FDA) in 2021.”

Mr. Joyce has two decades of public
company CEO and corporate board leadership experience.  Specific to blood purification therapies, Mr.
Joyce is the founder, former Chairman and CEO of Aethlon Medical, a company he navigated
from a single shareholder start-up to Nasdaq-traded Company with 8000+ shareholders.
During his tenure at Aethlon, Mr. Joyce oversaw the development of the Hemopurifier®,
a first-in-class blood purification technology to address life-threatening viruses
and cancer-promoting exosomes. Under his leadership, the Hemopurifier® became the
first therapeutic candidate to be awarded two FDA “Breakthrough Device” designations
and was the first and only device to receive “Emergency Use Authorization” (EAU)
approval from both the FDA and Health Canada to treat Ebola virus. Time Magazine
named the Hemopurifier® one of the “11 Most Remarkable Advances in Healthcare” and
designated the device to its “Top 25 Best Inventions” award list.

Sigyn Therapy was developed by Mr.
Joyce and Sigyn Chief Technical Officer, Craig Roberts.  Collectively, they have 50+ years of experience
in the medical technology field and played instrumental roles in the development
of three device technologies that have been cleared by the FDA to treat COVID-19
infected individuals.

In connection with the closing of
the merger, Sigyn has approximately 34 million shares of common stock issued and
outstanding with prior Sigyn equity-holders collectively owning approximately 75%
of the combined company on a fully-diluted basis, and Reign equity-holders collectively
owning approximately 25% of the combined company on a fully-diluted basis.

About Sigyn Therapeutics

Sigyn Therapeutics is a development-stage
therapeutic technology company headquartered in San Diego, California USA. Our focus
is directed toward a significant unmet need in global health; the treatment of life-threatening
inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not
addressed with an approved therapy. Our mission is to save lives.

Sigyn Therapy™ is a novel blood
purification technology designed to mitigate cytokine storm syndrome through the
broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine
storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital
deaths and claims more lives each year than all forms of cancer combined.  Virus induced cytokine storm (VICS) is associated
with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other
therapeutic opportunities include, but are not limited to bacteria induced cytokine
storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver
failure, such as hepatic encephalopathy.

To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com

Cautionary Note Regarding Forward-Looking
Statements

This press release contains forward-looking
statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks
and uncertainties. All statements contained in this press release are forward-looking
statements within the meaning of The Private Securities Litigation Reform Act of
1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,”
“expect,” “potential,” or the negative of these terms or other similar expressions
are intended to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. These forward-looking statements include,
among others, statements about Sigyn’s future financial performance, the impact
of management changes, any proposed organizational restructuring, results of operations,
capital resources to fund operations; statements about Sigyn’s expectations regarding
the capitalization, resources and ownership structure of the combined company; statements
about the potential benefits of the transaction; the expected completion and timing
of the transaction and other information relating to the transaction; and any other
statements other than statements of historical fact. Actual results or events could
differ materially from the plans, intentions and expectations disclosed in the forward-looking
statements that Sigyn makes due to a number of important factors, including (i)
the risk that the transaction may not be completed in a timely manner or at all,
which may adversely affect Sigyn’s business and the price of the common stock of
Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the
transaction, (iii) the occurrence of any event, change or other circumstance that
could give rise to the termination of the merger agreement, (iv) risks related to
the ability to realize the anticipated benefits of the transaction, including the
risk that the businesses will not be integrated successfully, (v) the effect of
the announcement or pendency of the transaction on Sigyn’s business relationships,
operating results and business generally, (vi) risks that the proposed transaction
disrupts current plans and operations, (vii) risks related to the combined entity’s
ability to up-list to a national securities exchange, (viii) risks related to the
combined entity’s access to existing capital and fundraising prospects to fund its
ongoing operations, (ix) risks related to diverting management’s attention from
Sigyn’s ongoing business operations, (x) other business effects, including the effects
of industry, market, economic, political or regulatory conditions, future exchange
and interest rates, and changes in tax and other laws, regulations, rates and policies,
and (xi) the outcome of any legal proceedings that may be instituted against Sigyn
related to the merger agreement or the transaction. Further risks that could cause
actual results to differ materially from those matters expressed in or implied by
such forward-looking statements are discussed in “Risk Factors” and elsewhere in
the previous Reign Resources Corporation Quarterly Report on Form 10-Q for the quarter
ended June 30, 2020 and other reports filed with the SEC. The forward-looking statements
in this press release represent Sigyn’s views as of the date of this press release.
Sigyn anticipates that subsequent events and developments may cause its views to
change. However, while it may elect to update these forward-looking statements at
some point in the future, it specifically disclaims any obligation to do so. You
should, therefore, not rely on these forward-looking statements as representing
Sigyn’s views as of any date subsequent to the date of this press release.

Contact Sigyn Therapeutics, Inc.

Jim Joyce

Chairman, CEO

(619) 368-2000

jimjoyce@elevatescience.com

Source link

Tags
Show More

Related Articles

Back to top button
Close

Get Smallcap and Microcap News, Research, Trade Alerts & MORE, all 100% FREE!

Enter your email address to get started. All 100% Free.

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@smallcapsdaily.com